在庫拠点

New Jersey, USA
Czech Republic, EU
Mumbai, India

* 在庫状況によります

Documentation

MSDSをダウンロード

サンプルCOAをダウンロード

内容: HPLC、MASS/LC-MS、1H NMR、FT-IR、含量、構造解析レポート（SER）、および製品に応じた追加分析データ。

2484719-08-4Abiraterone Related Compound 5

● Under Development

カタログ番号:	VL830011
CAS番号:	2484719-08-4
分子式:	C24H31F3O6S
分子量:	504.56 g/mol

ご用件は何ですか?

RFQリストに追加

に関する追加情報 CAS 2484719-08-4

親薬物

Abiraterone

IUPAC名

(3S, 8R, 9S, 10R, 13S, 14S)-10, 13-dimethyl-17-(2-(((trifluoromethyl)sulfonyl)oxy)acetyl)-2, 3, 4, 7, 8, 9, 10, 11, 12, 13, 14, 15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate

薬局方同義語

N/A

Other Synonyms

Abiraterone Pregnenolone-16-ene Acetate 21-Triflate;P regna-5,16-dien-20-one, 3-(acetyloxy)-21-[[(trifluoromethyl)sulfonyl]oxy]-, (3Î²)

SMILES

CC(O[C@H]1CC[C@]2(C)[C@@]3([H])CC[C@]4(C)C(C(COS(=O)(C(F)(F)F)=O)=O)=CC[C@@]4([H])[C@]3([H])CC=C2C1)=O

InChI

InChI=1S/C24H31F3O6S/c1-14(28)33-16-8-10-22(2)15(12-16)4-5-17-18-6-7-20(23(18,3)11-9-19(17)22)21(29)13-32-34(30,31)24(25,26)27/h4,7,16-19H,5-6,8-13H2,1-3H3/t16-,17-,18-,19-,22-,23-/m0/s1

説明

Abiraterone Related Compound 5Â is poorly absorbed and is susceptible to hydrolysis by esterases and is an orally active inhibitor of the steroidal enzyme CYP17A1 that is used in the treatment of prostate cancer.

References

Thakur, Abhimanyu, et al. â€œAbiraterone Acetate in the Treatment of Prostate Cancer.â€ Biomedicine & Pharmacotherapy, vol. 101, May 2018, pp. 211â€“218, 10.1016/j.biopha.2018.02.067.